ClinBrain Secures RMB 68 Million Series A Funding Led by Zhenghai Capital and Ruijian Capital

On August 28, 2018, VCBeat (WeChat Official Account: vcbeat) learned that ClinBrain, a leading domestic medical big data company, announced it had completed an RMB 68 million Series A financing round in the first half of the year. The round was co-led by Zhenghai Capital and Ruijian Capital, with participation from Jingyi Shares, Guangrun Capital, and Huafang Capital.

Founded in 2013, Collinbray is a medical big data company headquartered in Shanghai, dedicated to the integration, governance, application, and services of medical big data. The company holds 21 software copyrights related to medical big data and has six additional pending patents. It served as the lead editor for the "Guidelines for the Construction and Practical Application of Shanghai Hospital Information Integration Platforms," issued by the Shanghai Municipal Health Commission, and participated in the development of the OMAHA medical terminology standards. The company’s founders have nearly two decades of experience in the healthcare industry, boasting extensive expertise in medical operations and product development, as well as strong capabilities in corporate management and marketing.

Colinbray specializes in medical big data services, enabling users to govern and leverage medical big data. The company continuously invests in key technologies, product development, and service implementation to deliver faster, more comprehensive, more accurate, and smarter data products and services, thereby creating sustained value for its users. Its core products include the Clinical Data Repository (CDR), Operational Data Repository (ODR), Research Data Repository (RDR), and Hospital Service Bus (HSB) integration platform. Additionally, it offers a suite of applications built upon these three data repositories to meet hospital needs in clinical care, research, management, and information technology, such as the Medical Big Data Search Engine System, Integrated Clinical Research Platform, Single-Disease Research System, Medical Big Data Visualization System, Medical Big Data Governance Platform, and Hospital Operations Management System.

The company’s products have been deployed among users across major regions in China, including dozens of tertiary and secondary general and specialized hospitals such as Shanghai Changhai Hospital, Fudan University Shanghai Cancer Center, the Second Affiliated Hospital of Wenzhou Medical University, Guangxi Zhuang Autonomous Region People’s Hospital, Chengdu Fifth People’s Hospital, Shanghai Mental Health Center, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and the International Peace Maternity and Child Health Hospital of the School of Medicine, Shanghai Jiao Tong University. The company has also participated in the development of regional health and medical big data platforms for the Jing’an District Health Commission in Shanghai and the Zhenjiang Municipal Health Commission. At Changhai Hospital, the company has integrated and governed more than 1.6 billion medical data records, with weekly data application usage exceeding 2,000 instances hospital-wide. Building on this foundation, the company has engaged in multiple international collaborative research projects on major diseases with institutions such as Johns Hopkins Hospital.

Medical big data serves as the cornerstone of medical artificial intelligence, a critical support for enhancing hospital efficiency and improving clinical diagnosis, treatment, and research capabilities, as well as the data foundation driving the development of industries such as pharmaceuticals, insurance, and medical devices. Over the past five years, Collibra has been deeply rooted in the frontlines of hospitals and Health Commissions, building comprehensive, high-quality medical big data platforms for its users. With a style characterized by humility, pragmatism, and innovation, it has become a leading expert in medical big data in China. Following this round of financing, Collibra will remain focused on the field of medical big data, continue to increase investment in product research and development, and expand its market across China. Upholding the core values of “customer first, teamwork, integrity and responsibility, and continuous innovation,” the company is committed to advancing medical progress and benefiting human health.

I. Zhenghai Capital

Zhenghai Capital, established in January 2008, is a professional venture capital firm specializing in equity investments in high-tech, high-growth, and innovative enterprises. The firm has managed 25 funds with a total scale exceeding RMB 6 billion, and has invested in more than 80 growing companies, among which 10 have completed initial public offerings (IPOs) and 3 are listed on the National Equities Exchange and Quotations (NEEQ). Zhenghai Capital was ranked among the Top 30 Best Venture Capital Firms in China by Forbes in 2017.

II. Ruijian Capital

Ruijian Capital was jointly initiated by Shanghai Pharmaceuticals and Ruili Investment. Shanghai Pharmaceuticals is a state-controlled listed company indirectly controlled by the Shanghai State-owned Assets Supervision and Administration Commission (SASAC), with businesses covering the entire pharmaceutical industry chain, including drug research and development, manufacturing, distribution, and retail. Ruili Investment is a private equity fund management company led by three major state-owned enterprise groups: Shanghai United Media Group, Shanghai Industrial Holdings, and Shanghai International Group. The primary fund managed by Ruijian Capital is the Shanghai Health and Medical Industry Investment Fund, which focuses on investments in the health and medical sector and has a scale exceeding RMB 3 billion.